UNITED LAB (03933) issues a profit warning, expecting a net profit of approximately 340 million yuan for the interim period.
Fosun Pharmaceutical (03933) announced that it expects the groups net profit for the six months ending June 30, 2026, to be approximately RMB 340 million, compared to a net profit of approximately RMB 1.893 billion for the six months ending June 30, 2025.
UNITED LAB (03933) announced that it expects the group's net profit for the six months ending June 30, 2026, to be approximately RMB 340 million, compared to a net profit of approximately RMB 1.893 billion for the six months ending June 30, 2025.
The decrease in net profit was affected by the decline in market prices and demand adjustments for intermediate products and active pharmaceutical ingredients. Additionally, licensing fee income from Novo Nordisk A/S for the first half of 2026 is expected to be around RMB 101 million, while the licensing fee income from Novo Nordisk for the first half of 2025 was approximately RMB 1.433 billion.
Related Articles
YTO INTL EXP (06123): Wang Lixiu resigned as a non-executive director.
NANSHAN AL INTL (02610) announced its interim results, with shareholders' profit attributable to them at $62.7 million, a decrease of 74.8% compared to the previous year.
TYSAN HOLDINGS (00687) will distribute an interim dividend of HKD 0.03 per share on September 25th.
YTO INTL EXP (06123): Wang Lixiu resigned as a non-executive director.
NANSHAN AL INTL (02610) announced its interim results, with shareholders' profit attributable to them at $62.7 million, a decrease of 74.8% compared to the previous year.
TYSAN HOLDINGS (00687) will distribute an interim dividend of HKD 0.03 per share on September 25th.
RECOMMEND
